MedTrace Logo

Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer

NCT00420563 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-03-16

No results posted yet for this study

Summary

The scope of the trial is to assess the free progression rate at 2 months for each group of patients.

Conditions

Interventions

DRUG

MEGESTROL

320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision

DRUG

CYCLOPHOSPHAMIDE

50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision

Sponsors & Collaborators

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • PENEL Nicolas, MD · Centre Oscar Lambret

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-25
Primary Completion
2011-01-19
Completion
2011-01-19

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420563 on ClinicalTrials.gov